SLC5A2 and hydrops fetalis: Consistent with our meta-analysis, recent meta-analyses reported that SGLT-2 inhibitors reduced the risk of hospitalization for HF and the composite of hospitalization for HF and CV death but not the risk of CV death or all-cause death in HFpEF patients [29], [30], [31], [32], [33].